Glenmark bets on respiratory drug, licensing deals to improve business

Glenmark had gross debt of ₹3,765 crore as of June 30, 2022. The company over the years accumulated debt to fund its innovation-led R&D and fund capex, but with growth in key US market stuttering, it has been focusing on cutting debt and improving cash flows. In FY22, Glenmark reduced its debt by around ₹1,200 crore.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news